Registered number
10806017
T&S PHARMA LTD
Filleted Accounts
30 June 2024
T&S PHARMA LTD
Registered number: 10806017
Balance Sheet
as at 30 June 2024
Notes 2024 2023
£ £
Current assets
Debtors 3 36,310 -
Cash at bank and in hand 11,812 1,875
48,122 1,875
Creditors: amounts falling due within one year 4 (45,607) (1,099)
Net current assets 2,515 776
Net assets 2,515 776
Capital and reserves
Called up share capital 100 100
Profit and loss account 2,415 676
Shareholders' funds 2,515 776
The director is satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.
The members have not required the company to obtain an audit in accordance with section 476 of the Act.
The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
The accounts have been prepared and delivered in accordance with the special provisions applicable to companies subject to the small companies regime. The profit and loss account has not been delivered to the Registrar of Companies.
T. KOLLI
Director
Approved by the board on 25 March 2025
T&S PHARMA LTD
Notes to the Accounts
for the year ended 30 June 2024
1 Accounting policies
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Turnover
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the rendering of services. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Creditors
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
Taxation
A current tax liability is recognised for the tax payable on the taxable profit of the current and past periods. A current tax asset is recognised in respect of a tax loss that can be carried back to recover tax paid in a previous period. Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.
2 Employees 2024 2023
Number Number
Average number of persons employed by the company 2 1
3 Debtors 2024 2023
£ £
Trade debtors 26,310 -
Other debtors 10,000 -
36,310 -
4 Creditors: amounts falling due within one year 2024 2023
£ £
Taxation and social security costs 40,982 159
Other creditors 4,625 940
45,607 1,099
5 Other information
T&S PHARMA LTD is a private company limited by shares and incorporated in England. Its registered office is:
15 Springbank Road
Lane End
High Wycombe
Buckinghamshire
HP14 3GB
T&S PHARMA LTD 10806017 false 2023-07-01 2024-06-30 2024-06-30 VT Final Accounts July 2024 T. KOLLI No description of principal activity 10806017 2022-07-01 2023-06-30 10806017 core:WithinOneYear 2023-06-30 10806017 core:ShareCapital 2023-06-30 10806017 core:RetainedEarningsAccumulatedLosses 2023-06-30 10806017 2023-07-01 2024-06-30 10806017 bus:PrivateLimitedCompanyLtd 2023-07-01 2024-06-30 10806017 bus:AuditExemptWithAccountantsReport 2023-07-01 2024-06-30 10806017 bus:Director40 2023-07-01 2024-06-30 10806017 2 2023-07-01 2024-06-30 10806017 countries:England 2023-07-01 2024-06-30 10806017 bus:FRS102 2023-07-01 2024-06-30 10806017 bus:FilletedAccounts 2023-07-01 2024-06-30 10806017 2024-06-30 10806017 core:WithinOneYear 2024-06-30 10806017 core:ShareCapital 2024-06-30 10806017 core:RetainedEarningsAccumulatedLosses 2024-06-30 10806017 2023-06-30 iso4217:GBP xbrli:pure